ABSI logo

Absci Corporation (ABSI)

$10.21

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on ABSI

Market cap

$1.59B

EPS

-0.82

P/E ratio

--

Price to sales

421.22

Dividend yield

--

Beta

2.456709

Price on ABSI

Previous close

$10.08

Today's open

$11

Day's range

$9.32 - $11.25

52 week range

$2.24 - $11.25

Profile about ABSI

CEO

Sean Mcclain

Employees

156

Headquarters

Vancouver, WA

Exchange

Nasdaq Global Select

Shares outstanding

155905056

Issue type

Common Stock

ABSI industries and sectors

Healthcare

Biotechnology & Life Sciences

News on ABSI

Healthcare stocks have become a haven for investors ditching tech

Shares of AbbVie, Eli Lilly and Johnson & Johnson were on track to hit all-time highs Friday, in the latest signal that investor appetite for the biopharmaceutical sector is back.

news source

Market Watch • 13 hours ago

news preview

ABSCI CORP (ABSI) Soars 36.0%: Is Further Upside Left in the Stock?

ABSCI CORP (ABSI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

news source

Zacks Investment Research • Jun 25, 2026

news preview

ABSI Soars 36% on Positive Interim Update From Phase I Hair Loss Study

Absci stock jumps 36% as interim phase I hair loss study data show ABS-201 is well tolerated and pharmacokinetics support the potential for infrequent dosing.

news source

Zacks Investment Research • Jun 25, 2026

news preview

Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program

Absci Corporation (NASDAQ:ABSI) stock is trading higher on Wednesday after the company reported positive interim Phase 1 results for its investigational anti-prolactin receptor antibody, ABS-201, while also pricing a $100 million underwritten stock offering to support continued development of the program.

news source

Benzinga • Jun 24, 2026

news preview

Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors

Eli Lilly & Company, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and large investment management firm invest $100 million in Absci

news source

GlobeNewsWire • Jun 24, 2026

news preview

Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)

Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts

news source

GlobeNewsWire • Jun 24, 2026

news preview

MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery

AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #ai--MindWalk Holdings Corp. (“MindWalk”) (NASDAQ: HYFT), a bio-native AI company, today announced that President and Chief Executive Officer Dr. Jennifer Bath will join a virtual panel hosted by Jones, alongside Absci (NASDAQ: ABSI) and a leading AI compute provider, as part of Jones AI Day. The panel, “Partnering to Power the New Era of Drug Discovery,” will be held on Monday, June 15, 2026, at 12:00 p.m. ET. Moderated by Jones Research Senior Research Analysts Dr.

news source

Business Wire • Jun 12, 2026

news preview

Absci Corporation (ABSI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript

Absci Corporation (ABSI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript

news source

Seeking Alpha • Jun 10, 2026

news preview

Absci Corporation (ABSI) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript

Absci Corporation (ABSI) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript

news source

Seeking Alpha • Jun 5, 2026

news preview

Absci to Participate in Upcoming Investor Conferences

VANCOUVER, Wash. and NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will be participating in the following upcoming investor conferences:

news source

GlobeNewsWire • May 20, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Absci Corporation

Open an M1 investment account to buy and sell Absci Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in ABSI on M1